Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2012

Open Access 01-12-2012 | Minireview

The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department

Authors: Christian H Nickel, Roland Bingisser, Nils G Morgenthaler

Published in: BMC Medicine | Issue 1/2012

Login to get access

Abstract

The hypothalamic-pituitary-adrenal axis is activated in response to stress. One of the activated hypothalamic hormones is arginine vasopressin, a hormone involved in hemodynamics and osmoregulation. Copeptin, the C-terminal part of the arginine vasopressin precursor peptide, is a sensitive and stable surrogate marker for arginine vasopressin release. Measurement of copeptin levels has been shown to be useful in a variety of clinical scenarios, particularly as a prognostic marker in patients with acute diseases such as lower respiratory tract infection, heart disease and stroke. The measurement of copeptin levels may provide crucial information for risk stratification in a variety of clinical situations. As such, the emergency department appears to be the ideal setting for its potential use. This review summarizes the recent progress towards determining the prognostic and diagnostic value of copeptin in the emergency department.
Appendix
Available only for authorised users
Literature
1.
Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Muller B: Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004, 363 (9409): 600-607. 10.1016/S0140-6736(04)15591-8.CrossRefPubMed
2.
Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B: Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009, 302 (10): 1059-1066. 10.1001/jama.2009.1297.CrossRefPubMed
3.
Land H, Schutz G, Schmale H, Richter D: Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursor. Nature. 1982, 295 (5847): 299-303. 10.1038/295299a0.CrossRefPubMed
4.
Gillies GE, Linton EA, Lowry PJ: Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature. 1982, 299 (5881): 355-357. 10.1038/299355a0.CrossRefPubMed
5.
Rivier C, Vale W: Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature. 1983, 305 (5932): 325-327. 10.1038/305325a0.CrossRefPubMed
6.
Rivier C, Vale W: Interaction of corticotropin-releasing factor and arginine vasopressin on adrenocorticotropin secretion in vivo. Endocrinology. 1983, 113 (3): 939-942. 10.1210/endo-113-3-939.CrossRefPubMed
7.
Milsom SR, Conaglen JV, Donald RA, Espiner EA, Nicholls MG, Livesey JH: Augmentation of the response to CRF in man: relative contributions of endogenous angiotensin and vasopressin. Clin Endocrinol (Oxf). 1985, 22 (5): 623-629. 10.1111/j.1365-2265.1985.tb02998.x.CrossRef
8.
Schuetz P, Muller B: The hypothalamic-pituitary-adrenal axis in critical illness. Endocrinol Metab Clin North Am. 2006, 35 (4): 823-838. 10.1016/j.ecl.2006.09.013. xCrossRefPubMed
9.
Christ-Crain M, Stolz D, Jutla S, Couppis O, Muller C, Bingisser R, Schuetz P, Tamm M, Edwards R, Muller B, Grossman AB: Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med. 2007, 176 (9): 913-920. 10.1164/rccm.200702-307OC.CrossRefPubMed
10.
Katan M, Morgenthaler N, Widmer I, Puder JJ, Konig C, Muller B, Christ-Crain M: Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett. 2008, 29 (3): 341-346.PubMed
11.
Struck J, Morgenthaler NG, Bergmann A: Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides. 2005, 26 (12): 2500-2504. 10.1016/j.peptides.2005.04.019.CrossRefPubMed
12.
Morgenthaler NG, Struck J, Alonso C, Bergmann A: Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006, 52 (1): 112-119. 10.1373/clinchem.2005.060038.CrossRefPubMed
13.
Birnbaumer M: Vasopressin receptors. Trends Endocrinol Metab. 2000, 11 (10): 406-410. 10.1016/S1043-2760(00)00304-0.CrossRefPubMed
14.
Thibonnier M, Preston JA, Dulin N, Wilkins PL, Berti-Mattera LN, Mattera R: The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997, 138 (10): 4109-4122. 10.1210/en.138.10.4109.PubMed
15.
Morgenthaler NG, Muller B, Struck J, Bergmann A, Redl H, Christ-Crain M: Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock. 2007, 28 (2): 219-226. 10.1097/SHK.0b013e318033e5da.CrossRefPubMed
16.
Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG, Bergmann A, Potocki M, Noveanu M, Breidthardt T, Christ A, Boldanova T, Merki R, Schaub N, Bingisser R, Christ M, Mueller C: Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol. 2009, 54 (1): 60-68. 10.1016/j.jacc.2009.01.076.CrossRefPubMed
17.
Keller T, Tzikas S, Zeller T, Czyz E, Lillpopp L, Ojeda FM, Roth A, Bickel C, Baldus S, Sinning CR, Wild PS, Lubos E, Peetz D, Kunde J, Hartmann O, Bergmann A, Post F, Lackner KJ, Genth-Zotz S, Nicaud V, Tiret L, Munzel TF, Blankenberg S: Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol. 2010, 55 (19): 2096-2106. 10.1016/j.jacc.2010.01.029.CrossRefPubMed
18.
Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, Biedert S, Schaub N, Buerge C, Potocki M, Noveanu M, Breidthardt T, Twerenbold R, Winkler K, Bingisser R, Mueller C: Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009, 361 (9): 858-867. 10.1056/NEJMoa0900428.CrossRefPubMed
19.
Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, Bickel C, Baldus S, Warnholtz A, Frohlich M, Sinning CR, Eleftheriadis MS, Wild PS, Schnabel RB, Lubos E, Jachmann N, Genth-Zotz S, Post F, Nicaud V, Tiret L, Lackner KJ, Munzel TF, Blankenberg S: Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med. 2009, 361 (9): 868-877. 10.1056/NEJMoa0903515.CrossRefPubMed
20.
Jaffe AS, Apple FS: High-sensitivity cardiac troponin: hype, help, and reality. Clin Chem. 56 (3): 342-344.
21.
Giannitsis E, Kehayova T, Vafaie M, Katus HA: Combined testing of high-sensitivity troponin T and copeptin on presentation at prespecified cutoffs improves rapid rule-out of non-ST-segment elevation myocardial infarction. Clin Chem. 2011, 57 (10): 1452-1455. 10.1373/clinchem.2010.161265.CrossRefPubMed
22.
Stoiser B, Mortl D, Hulsmann M, Berger R, Struck J, Morgenthaler NG, Bergmann A, Pacher R: Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest. 2006, 36 (11): 771-778. 10.1111/j.1365-2362.2006.01724.x.CrossRefPubMed
23.
Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, Haltmayer M, Mueller T: Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail. 2007, 13 (1): 42-49. 10.1016/j.cardfail.2006.09.004.CrossRefPubMed
24.
Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Ng LL: C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation. 2007, 115 (16): 2103-2110. 10.1161/CIRCULATIONAHA.106.685503.CrossRefPubMed
25.
Voors AA, von Haehling S, Anker SD, Hillege HL, Struck J, Hartmann O, Bergmann A, Squire I, van Veldhuisen DJ, Dickstein K: C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J. 2009, 30 (10): 1187-1194. 10.1093/eurheartj/ehp098.CrossRefPubMed
26.
Tentzeris I, Jarai R, Farhan S, Perkmann T, Schwarz MA, Jakl G, Wojta J, Huber K: Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure. Eur J Heart Fail. 2011, 13 (7): 726-733. 10.1093/eurjhf/hfr049.CrossRefPubMed
27.
Alehagen U, Dahlstrom U, Rehfeld JF, Goetze JP: Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA. 2011, 305 (20): 2088-2095. 10.1001/jama.2011.666.CrossRefPubMed
28.
Maisel A, Xue Y, Shah K, Mueller C, Nowak R, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng L, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, von Haehling S, Bergmann A, Morgenthaler NG, Anker SD: Increased 90-Day mortality in acute heart failure patients with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) Study. Circ Heart Fail. 2011, 4 (5): 613-620. 10.1161/CIRCHEARTFAILURE.110.960096.CrossRefPubMed
29.
Vachharajani TJ, Zaman F, Abreo KD: Hyponatremia in critically ill patients. J Intensive Care Med. 2003, 18 (1): 3-8. 10.1177/0885066602239119.CrossRefPubMed
30.
Fenske W, Stork S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B: Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab. 2009, 94 (1): 123-129.CrossRefPubMed
31.
Fenske W, Quinkler M, Lorenz D, Zopf K, Haagen U, Papassotiriou J, Pfeiffer AF, Fassnacht M, Stork S, Allolio B: Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome--revisiting the direct and indirect water deprivation tests. J Clin Endocrinol Metab. 2011, 96 (5): 1506-1515. 10.1210/jc.2010-2345.CrossRefPubMed
32.
Katan M, Morgenthaler NG, Dixit KC, Rutishauser J, Brabant GE, Muller B, Christ-Crain M: Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay. J Clin Endocrinol Metab. 2007, 92 (7): 2640-2643. 10.1210/jc.2006-2046.CrossRefPubMed
33.
Nigro N, Muller B, Morgenthaler NG, Fluri F, Schutz P, Neidert S, Stolz D, Bingisser R, Tamm M, Christ-Crain M, Katan M: The use of copeptin, the stable peptide of the vasopressin precursor, in the differential diagnosis of sodium imbalance in patients with acute diseases. Swiss Med Wkly. 2011, 141: w13270.PubMed
34.
Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R, Muller C, Struck J, Muller B, Tamm M: Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest. 2007, 131 (4): 1058-1067. 10.1378/chest.06-2336.CrossRefPubMed
35.
Muller B, Morgenthaler N, Stolz D, Schuetz P, Muller C, Bingisser R, Bergmann A, Tamm M, Christ-Crain M: Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest. 2007, 37 (2): 145-152. 10.1111/j.1365-2362.2007.01762.x.CrossRefPubMed
36.
Katan M, Nigro N, Fluri F, Schuetz P, Morgenthaler NG, Jax F, Meckel S, Gass A, Bingisser R, Steck A, Kappos L, Engelter S, Muller B, Christ-Crain M: Stress hormones predict cerebrovascular re-events after transient ischemic attacks. Neurology. 2011, 76 (6): 563-566. 10.1212/WNL.0b013e31820b75e6.CrossRefPubMed
37.
Urwyler SA, Schuetz P, Fluri F, Morgenthaler NG, Zweifel C, Bergmann A, Bingisser R, Kappos L, Steck A, Engelter S, Muller B, Christ-Crain M, Katan M: Prognostic value of copeptin: one-year outcome in patients with acute stroke. Stroke. 2010, 41 (7): 1564-1567. 10.1161/STROKEAHA.110.584649.CrossRefPubMed
38.
Dong XQ, Huang M, Yang SB, Yu WH, Zhang ZY: Copeptin is associated with mortality in patients with traumatic brain injury. J Trauma. 2011, 71 (5): 1194-1198. 10.1097/TA.0b013e31821283f2.CrossRefPubMed
39.
Aminzadeh F, Dalziel WB: Older adults in the emergency department: a systematic review of patterns of use, adverse outcomes, and effectiveness of interventions. Ann Emerg Med. 2002, 39 (3): 238-247. 10.1067/mem.2002.121523.CrossRefPubMed
40.
Nemec M, Koller MT, Nickel CH, Maile S, Winterhalder C, Karrer C, Laifer G, Bingisser R: Patients presenting to the emergency department with non-specific complaints: the Basel Non-specific Complaints (BANC) study. Acad Emerg Med. 2010, 17 (3): 284-292. 10.1111/j.1553-2712.2009.00658.x.CrossRefPubMed
41.
Nickel CH, Ruedinger J, Misch F, Blume K, Maile S, Schulte J, Kohrle J, Hartmann O, Giersdorf S, Bingisser R: Copeptin and peroxiredoxin-4 independently predict mortality in patients with nonspecific complaints presenting to the emergency department. Acad Emerg Med. 2011, 18 (8): 851-859. 10.1111/j.1553-2712.2011.01126.x.CrossRefPubMed
42.
Nickel CH, Nemec M, Bingisser R: Weakness as presenting symptom in the emergency department. Swiss Med Wkly. 2009, 139 (17-18): 271-272.PubMed
43.
Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng L, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, von Haehling S, Bergmann A, Morgenthaler NG, Anker SD: Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010, 55 (19): 2062-2076. 10.1016/j.jacc.2010.02.025.CrossRefPubMed
44.
Peacock WF, Nowak R, Christenson R, DiSomma S, Neath SX, Hartmann O, Mueller C, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Filippatos GS, Anand I, Ng LL, Daniels LB, Morgenthaler N, Anker SD, Maisel AS: Short-term mortality risk in emergency department acute heart failure. Acad Emerg Med. 2011, 18 (9): 947-958. 10.1111/j.1553-2712.2011.01150.x.CrossRefPubMed
45.
Januzzi JL, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, O'Donoghue M, Sakhuja R, Chen AA, van Kimmenade RR, Lewandrowski KB, Lloyd-Jones DM, Wu AH: Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol. 2007, 50 (7): 607-613. 10.1016/j.jacc.2007.05.014.CrossRefPubMed
46.
Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, Lindahl B, Horn-Wichmann R, Brabant G, Simoons ML, Armstrong PW, Califf RM, Drexler H, Wallentin L: Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007, 115 (8): 962-971. 10.1161/CIRCULATIONAHA.106.650846.CrossRefPubMed
47.
Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL: Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond). 2009, 116 (3): 257-263. 10.1042/CS20080140.CrossRef
48.
de Kruif MD, Lemaire LC, Giebelen IA, Struck J, Morgenthaler NG, Papassotiriou J, Elliott PJ, van der Poll T: The influence of corticosteroids on the release of novel biomarkers in human endotoxemia. Intensive Care Med. 2008, 34 (3): 518-522. 10.1007/s00134-007-0955-x.CrossRefPubMed
49.
Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, Muller K, Meckel S, Gass A, Kappos L, Steck AJ, Engelter ST, Muller B, Christ-Crain M: Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol. 2009, 66 (6): 799-808.CrossRefPubMed
50.
Zweifel C, Katan M, Schuetz P, Siegemund M, Morgenthaler NG, Merlo A, Mueller B, Christ-Crain M: Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage. BMC Neurol. 2010, 10: 34-10.1186/1471-2377-10-34.CrossRefPubMedPubMedCentral
Metadata
Title
The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department
Authors
Christian H Nickel
Roland Bingisser
Nils G Morgenthaler
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2012
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/1741-7015-10-7

Other articles of this Issue 1/2012

BMC Medicine 1/2012 Go to the issue

Opinion

Does the oxytocin receptor polymorphism (rs2254298) confer 'vulnerability' for psychopathology or 'differential susceptibility'? insights from evolution

Research article

Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review

Research article

Insufficient maintenance DNA methylation is associated with abnormal embryonic development

Research article

Co-prescription of medication for bipolar disorder and diabetes mellitus: a nationwide population-based study with focus on gender differences

Opinion

Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression

Research article

Estimation of outbreak severity and transmissibility: Influenza A(H1N1)pdm09 in households